In this study, we aim to identify the clinical significance of basonuclin 1 (BNC1) expression in ovarian carcinoma (OV) and to explore its latent mechanisms. Via integrating in-house tissue microarrays, gene chips, and RNA-sequencing data, we explored the expression and clinical value of BNC1 in OV. Immunohistochemical staining was utilized to confirm the protein expression status of BNC1. A combined SMD of –2.339 (95% CI: –3.649 to –1.028, P <0.001) identified that BNC1 was downregulated based on 1346 samples, and the sROC (AUC = 0.93) showed a favorable discriminatory ability of BNC1 in OV patients. We used univariate and multivariate Cox regulation to evaluate the prognostic role of BNC1 for OV patients, and a combined hazard ratio of 0.717 (95% CI: 0.445–0.989, P <0.001) revealed that BNC1 was a protective factor for OV. Furthermore, the fraction of infiltrating naive B cells, memory B cells, and other immune cells showed statistical differences between the high- and low-BNC1 expression groups through cell-type identification by estimating relative subsets of RNA transcripts (CIBERSORT) algorithm. Enrichment analysis showed that BNC1 may have a relationship with immune-related items in OV. By predicting the potential regulatory transcription factors (TFs) of BNC1, friend leukemia virus integration 1 (FLI1) may be a potential upstream TF of BNC1. Corporately, a decreasing trend of BNC1 may serve as a tumor suppressor and prognostic biomarker in OV patients. Moreover, BNC1 may take part in immune-related pathways and influence the fraction of tumor-infiltrating immune cells.
SiegelRLMillerKDFuchsHEJemalA.Cancer statistics, 2021. CA A Cancer J Clin2021;
71:7–33
2.
TorreLATrabertBDeSantisCEMillerKDSamimiGRunowiczCDGaudetMMJemalASiegelRL.Ovarian cancer statistics, 2018. CA Cancer J Clin2018;
68:284–96
3.
KurokiLGuntupalliSR.Treatment of epithelial ovarian cancer. Bmj2020;
371:m3773
4.
LiDHongXZhaoFCiXZhangS.Targeting Nrf2 may reverse the drug resistance in ovarian cancer. Cancer Cell Int2021;
21:116
5.
FlorentRWeiswaldL-BLambertBBrotinEAbeilardELouisM-HBabinGPoulainL, NM.Bim, puma and noxa upregulation by naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor trametinib. Cell Death Dis2020;
11:380
6.
SunTBiFLiuZYangQ.TMEM119 facilitates ovarian cancer cell proliferation, invasion, and migration via the PDGFRB/PI3K/AKT signaling pathway. J Transl Med2021;
19:111
7.
DingBYuanFDamlePKLitovchickLDrapkinRGrossmanSR.CtBP determines ovarian cancer cell fate through repression of death receptors. Cell Death Dis2020;
11:286
8.
Delgado-OrtegaLGonzalez-DominguezABorrasJMOliva-MorenoJGonzalez-HabaEMenjonSPerezPVicenteDCorderoLJimenezMSimonSHidalgo-VegaAMoya-AlarconC.The economic burden of disease of epithelial ovarian cancer in Spain: the OvarCost study. Eur J Health Econ2019;
20:135–47
9.
MaJZengFSchultzRMTsengH.Basonuclin: a novel mammalian maternal-effect gene. Development2006;
133:2053–62
10.
ZhangDLiuYZhangZLvPLiuYLiJWuYZhangRHuangYXuGQianYQianYChenSXuCShenJZhuLChenKZhuBYeXMaoYBoXZhouCWangTChenDYangWTanYSongYZhouDShengJGaoHZhuYLiMWuLHeLHuangH.Basonuclin 1 deficiency is a cause of primary ovarian insufficiency. Hum Mol Genet2018;
27:3787–800
11.
LiJYLiuYFXuHYZhangJYLvPPLiuMEYingYYQianYQLiKLiCHuangYXuGFDingGLMaoYCXuCMLiuXMShengJZZhangDHuangHF.Basonuclin 1 deficiency causes testicular premature aging: BNC1 cooperates with TAF7L to regulate spermatogenesis. J Mol Cell Biol2020;
12:71–83
12.
García-DíezIHernández-MuñozIHernández-RuizENonellLPuigdecanetEBódalo-TorruellaMAndradesEPujolRMTollA.Transcriptome and cytogenetic profiling analysis of matched in situ/invasive cutaneous squamous cell carcinomas from immunocompetent patients. Genes Chromosomes Cancer2019;
58:164–74
13.
PangeniRPChannathodiyilPHuenDSEaglesLWJohalBKPashaDHadjistephanouNNevellODaviesCLAdewumiAIKhanomHSamraISBuzattoVCChandrasekaranPShinawiTDawsonTPAshtonKMDavisCBrodbeltARJenkinsonMDBiecheILatifFDarlingJLWarrTJMorrisMR.The GALNT9, BNC1 and CCDC8 genes are frequently epigenetically dysregulated in breast tumours that metastasise to the brain. Clin Epigenetics2015;
7:57
14.
GheorgheGBungauSIlieMBehlTVesaCMBriscCBacalbasaNTuriVCostacheRSDiaconuCC.Early diagnosis of pancreatic cancer: the key for survival. Diagnostics (Basel)2020;
10:869
15.
LiangLZhaoKZhuJ-HChenGQinX-GChenJ-Q.Comprehensive evaluation of FKBP10 expression and its prognostic potential in gastric cancer. Oncol Rep2019;
42:615–28
16.
HouXYangLJiangXLiuZLiXXieSLiGLiuJ.Role of microRNA-141-3p in the progression and metastasis of hepatocellular carcinoma cell. Int J Biol Macromol2019;
128:331–9
17.
GautierLCopeLBolstadBMIrizarryRA.Affy – analysis of affymetrix GeneChip data at the probe level. Bioinformatics2004;
20:307–15
18.
LeekJTJohnsonWEParkerHSJaffeAEStoreyJD.The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics2012;
28:882–3
19.
LiuRHuRZengYZhangWZhouH-H.Tumour immune cell infiltration and survival after platinum-based chemotherapy in high-grade serous ovarian cancer subtypes: a gene expression-based computational study. EBioMedicine2020;
51:102602
20.
NewmanAMLiuCLGreenMRGentlesAJFengWXuYHoangCDDiehnMAlizadehAA.Robust enumeration of cell subsets from tissue expression profiles. Nat Methods2015;
12:453–7
21.
SubramanianATamayoPMoothaVKMukherjeeSEbertBLGilletteMAPaulovichAPomeroySLGolubTRLanderESMesirovJP.Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA2005;
102:15545–50
22.
ZhengRWanCMeiSQinQWuQSunHChenC-HBrownMZhangXMeyerCALiuXS.Cistrome data browser: expanded datasets and new tools for gene regulatory analysis. Nucleic Acids Res2019;
47:D729–35
23.
MeiSQinQWuQSunHZhengRZangCZhuMWuJShiXTaingLLiuTBrownMMeyerCALiuXS.Cistrome data browser: a data portal for ChIP-Seq and chromatin accessibility data in human and mouse. Nucleic Acids Res2017;
45:D658–62
24.
FornesOCastro-MondragonJAKhanAvan der LeeRZhangXRichmondPAModiBPCorreardSGheorgheMBaranašićDSantana-GarciaWTanGChènebyJBallesterBParcyFSandelinALenhardBWassermanWWMathelierA.JASPAR 2020: update of the open-access database of transcription factor binding profiles. Nucleic Acids Res2020;
48:D87–92
25.
GrantCEBaileyTLNobleWS.FIMO: scanning for occurrences of a given motif. Bioinformatics2011;
27:1017–8
26.
BaileyTLBodenMBuskeFAFrithMGrantCEClementiLRenJLiWWNobleWS.MEME SUITE: tools for motif discovery and searching. Nucleic Acids Res2009;
37:W202–W08
27.
WuYZhangXLiuYLuFChenX.Decreased expression of BNC1 and BNC2 is associated with genetic or epigenetic regulation in hepatocellular carcinoma. Ijms2016;
17:153
28.
YiJMGuzzettaAABaileyVJDowningSRVan NesteLChiappinelliKBKeeleyBPStarkAHerreraAWolfgangCPappouEPIacobuzio-DonahueCAGogginsMGHermanJGWangTHBaylinSBAhujaN.Novel methylation biomarker panel for the early detection of pancreatic cancer. Clin Cancer Res2013;
19:6544–55
29.
BoldrupLCoatesPJLaurellGNylanderK.p63 transcriptionally regulates BNC1, a pol I and pol II transcription factor that regulates ribosomal biogenesis and epithelial differentiation. Eur J Cancer2012;
48:1401–6
30.
YuanFLuLZouQ.Analysis of gene expression profiles of lung cancer subtypes with machine learning algorithms. Biochim Biophys Acta Mol Basis Dis2020;
1866:165822
31.
MorrisMRRickettsCGentleDAbdulrahmanMClarkeNBrownMKishidaTYaoMLatifFMaherER.Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene2010;
29:2104–17
32.
RickettsCJHillVKLinehanWM.Tumor-specific hypermethylation of epigenetic biomarkers, including SFRP1, predicts for poorer survival in patients from the TCGA kidney renal clear cell carcinoma (KIRC) project. PLoS One2014;
9:e85621
33.
GhisoniEImbimboMZimmermannSValabregaG.Ovarian cancer immunotherapy: Turning up the heat. Ijms2019;
20:2927
34.
PagèsFGalonJDieu-NosjeanMCTartourESautès-FridmanCFridmanWH.Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene2010;
29:1093–102
35.
GuptaPChenCChaluvally-RaghavanPPradeepS.B cells as an immune-regulatory signature in ovarian cancer. Cancers (Basel)2019;
11:894
36.
GundersonAJCoussensLM.B cells and their mediators as targets for therapy in solid tumors. Exp Cell Res2013;
319:1644–9
37.
NielsenJSSahotaRAMilneKKostSENesslingerNJWatsonPHNelsonBH.CD20+ tumor-infiltrating lymphocytes have an atypical CD27-memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res2012;
18:3281–92
38.
TokunagaRNaseemMLoJHBattaglinFSoniSPucciniABergerMDZhangWBabaHLenzH-J.B cell and B cell-related pathways for novel cancer treatments. Cancer Treat Rev2019;
73:10–9
39.
WangS-SLiuWLyDXuHQuLZhangL.Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer. Cell Mol Immunol2019;
16:18
40.
ZhuWGermainCLiuZSebastianYDeviPKnockaertSBrohawnPLehmannKDamotteDValidirePYaoYValge-ArcherVHammondSADieu-NosjeanM-CHiggsBW.A high density of tertiary lymphoid structure B cells in lung tumors is associated with increased CD4 T cell receptor repertoire clonality. Oncoimmunology2015;
4:e1051922
41.
GermainCGnjaticSTamzalitFKnockaertSRemarkRGocJLepelleyABechtEKatsahianSBizouardGValidirePDamotteDAlifanoMMagdeleinatPCremerITeillaudJ-LFridmanW-HSautès-FridmanCDieu-NosjeanM-C.Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am J Respir Crit Care Med2014;
189:832–44
42.
EissaMALLernerLAbdelfatahEShankarNCannerJKHasanNMYaghoobiVHuangBKernerZTakaesuFWolfgangCKwakRRuizMTamMPisanicTR2ndIacobuzio-DonahueCAHrubanRHHeJWangTHWoodLDSharmaAAhujaN.Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood. Clin Epigenetics2019;
11:59
43.
ShamesDSGirardLGaoBSatoMLewisCMShivapurkarNJiangAPerouCMKimYHPollackJRFongKMLamC-LWongMShyrYNandaROlopadeOIGeraldWEuhusDMShayJWGazdarAFMinnaJD.A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med2006;
3:e486
44.
FeuerbornAMathowDSrivastavaPKGretzNGröneHJ.Basonuclin-1 modulates epithelial plasticity and TGF-β1-induced loss of epithelial cell integrity. Oncogene2015;
34:1185–95
KalluriRWeinbergRA.The basics of epithelial-mesenchymal transition. J Clin Invest2009;
119:1420–8
47.
CheonD-JTongYSimM-SDeringJBerelDCuiXLesterJBeachJATighiouartMWaltsAEKarlanBYOrsulicS.A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer. Clin Cancer Res2014;
20:711–23
48.
KanakkantharaAKurmiKEkstromTLHouXPurfeerstERHeinzenEPCorreiaCHuntoonCJO'BrienDWahner HendricksonAEDowdySCLiHObergALHitosugiTKaufmannSHWerohaSJKarnitzLM.BRCA1 deficiency upregulates NNMT, which reprograms metabolism and sensitizes ovarian cancer cells to mitochondrial metabolic targeting agents. Cancer Res2019;
79:5920–9
49.
EckertMACosciaFChryplewiczAChangJWHernandezKMPanSTiendaSMNahotkoDALiGBlaženovićILastraRRCurtisMYamadaSDPeretsRMcGregorSMAndradeJFiehnOMoelleringREMannMLengyelE.Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature2019;
569:723–8
50.
KarakashevSZhuHWuSYokoyamaYBitlerBGParkP-HLeeJ-HKossenkovAVGaonkarKSYanHDrapkinRConejo-GarciaJRSpeicherDWOrdogTZhangR.CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity. Nat Commun2018;
9:631
51.
MantovaniABarajonIGarlandaC.IL-1 and IL-1 regulatory pathways in cancer progression and therapy. Immunol Rev2018;
281:57–61
52.
VoronovEShouvalDSKrelinYCagnanoEBenharrochDIwakuraYDinarelloCAApteRN.IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA2003;
100:2645–50
53.
ZengQJewellCM.Directing toll-like receptor signaling in macrophages to enhance tumor immunotherapy. Curr Opin Biotechnol2019;
60:138–45
54.
RodellCBArlauckasSPCuccareseMFGarrisCSLiRAhmedMSKohlerRHPittetMJWeisslederR.TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nat Biomed Eng2018;
2:578–88
55.
Urban-WojciukZKhanMMOylerBLFåhraeusRMarek-TrzonkowskaNNita-LazarAHuppTRGoodlettDR.The role of TLRs in anti-cancer immunity and tumor rejection. Front Immunol2019;
10:2388
56.
MantovaniAMarchesiFMalesciALaghiLAllavenaP.Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol2017;
14:399–416
57.
DehneNMoraJNamgaladzeDWeigertABrüneB.Cancer cell and macrophage cross-talk in the tumor microenvironment. Curr Opin Pharmacol2017;
35:12–9
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
